Arbios | Market Potential

"Globally, there are an estimated 10 to 20 million hospitalizable episodes of liver failure every year. Physicians and patients must contend with insufficient donor organs for liver transplantation and insufficient treatment alternatives for otherwise managing patients. I am excited that Arbios is at the forefront of clinical breakthroughs in the field."

Achilles Demetriou, MD, Ph.D. Chief Operating Officer & EVP, University Hospitals Health System, Cleveland; Founder and Chairman of the Scientific Advisory Board, Arbios Systems, Inc.

North America OR Europe

Asia

Worldwide Market





"Globally, there are an estimated 10 to 20 million hospitalizable episodes of liver failure every year. Physicians and patients must contend with insufficient donor organs for liver transplantation and insufficient treatment alternatives for otherwise managing patients. I am excited that Arbios is at the forefront of clinical breakthroughs in the field." Achilles Demetriou, MD, Ph.D. Chief Operating Officer & EVP, University Hospitals Health System, Cleveland; Founder and Chairman of the Scientific Advisory Board, Arbios Systems, Inc.	Both SEPET™ and HepatAssist™, if successfully developed, could represent significant commercial opportunities. For the purposes of commercial opportunity assessment, the market is defined as follows: Acute Liver Failure Patients in critical need of transplant Acute-on-Chronic Liver Failure: Patients with episodic critical need Chronic Hepatitis B Chronic Hepatitis C Alcoholic Cirrhosis Prevention of Acute Liver Failure: Patients with progressive chronic liver disease North America OR Europe Asia Worldwide Market


	About Arbios \| Liver Disease \| Product Pipeline \| Investor/Media Relations \| Site Map \| Home \| Contact Us \| Terms of Use